I’ve spent the last five years shepherding Class IIa/IIb Technical Files through audits, answering notified‑body questions at odd hours, and patching gaps that only show up under Annex II scrutiny. To be fair, MDR’s intent — strengthen clinical evidence, tighten post‑market vigilance, raise the bar on documentation — is sensible. In practice this means more paperwork, but also clearer expectations if you stop treating CE as a tick‑box.

Here’s what is genuinely new under MDR, and where I see teams repeatedly going wrong.

What is actually new (or newly emphasised)

• PRRC (Article 15): You must have a Person Responsible for Regulatory Compliance with demonstrable expertise. This is not optional. In practice that means named responsibility, documented qualifications and visibility in your QMS.
• Stronger clinical requirements (Annex XIV): Clinical evaluation and Post‑Market Clinical Follow‑up (PMCF) are more demanding. Notified bodies now expect an evidence continuum — pre‑market clinical data, ongoing PMCF and periodic updates to the clinical evaluation report.
• Technical documentation expectations (Annex II): The Technical File needs to explicitly show conformity to the General Safety and Performance Requirements (Annex I). Traceability between requirements, risk controls, verification/validation and clinical evidence is inspected in detail.
• Classification vigilance (Annex VIII): Devices get re‑classified more often under MDR rules (software and rule changes, notably). You can’t assume legacy classification still applies.
• Post‑market system and reporting: PMS plans, continuous vigilance and Periodic Safety Update Reports are under closer review. The system is now a live obligation, not an annual add‑on.
• Implant cards and labelling: For implantable devices there are prescriptive requirements for what must be provided to patients and healthcare professionals (Article 18).
• UDI and EUDAMED readiness: UDI is mandated; EUDAMED and actor registration are the channels for transparency. Whether your team enters data or your regulator will find it, you still carry the duty.

What teams still get wrong

• “We just need more clinical studies.” Not always. Randomised controlled trials are ideal in some contexts but not required for every device. Annex XIV asks for appropriate clinical evidence and a demonstration that benefit–risk is acceptable. Appropriate can be bench tests, bench+clinical, post‑market data — justified and well‑documented.
• “Equivalence is simple.” Equivalence claims are heavily scrutinised. Notified bodies want comparative technical, biological and clinical justification — plus evidence you control the manufacturing and post‑market data of the equivalent device. In practice, relying on a competitor’s data without strong comparability is a dead end.
• “Harmonised standards = automatic compliance.” Harmonised standards give a presumption of conformity, but you must still demonstrate their proper application and address any residual risks per Annex I.
• “We can delay PMCF.” PMCF is part of clinical evaluation under Annex XIV: it’s proactively expected, proportionate to risk, and should be planned. Saying “we’ll do it later” raises flags at audit.
• “A CE certificate is forever.” Certificates have validity, surveillance, and re‑assessment triggers (major changes, significant incidents). Treat them as conditional, not permanent.
• “EUDAMED will sort transparency for us.” Don’t rely on EUDAMED as a safety net. Your PMS, vigilance reporting and UDI duties stay with you; a database is a tool, not a compliance strategy.

Practical steps that actually survive an audit

• Map Annex I to your product: create a Requirements‑to‑Evidence matrix linking each Annex I requirement to risk controls, verification activities and supporting clinical data. This is the single best control for Annex II audits.
• Formalise your PRRC role: include a job description, qualifications record and documented responsibilities in your QMS. Auditors ask for this explicitly (Article 15).
• Treat clinical evaluation as iterative: maintain a living Clinical Evaluation Report (CER) and PMCF plan. Record the rationale when you decide observational PMCF is sufficient versus a prospective clinical study.
• Use a traceability tool: whether an eQMS or a simple spreadsheet, ensure traceability across change control, CAPA, risk management and technical documentation. Connected workflow reduces audit surprises and speeds up evidence retrieval.
• Be explicit on equivalence: if you claim equivalence, document the technical, clinical and manufacturing comparators, plus a justification for using their data. If you can’t, plan your own clinical evidence pathway.
• Integrate PMS outputs into CER: post‑market data should feed clinical evaluation and risk management. Make the loop visible — incident → investigation → CAPA → risk assessment → CER update.

A final, practical note on QMS tooling

An eQMS that supports automated CAPAs, traceability and change impact analysis is not a silver bullet, but it makes life far easier. Look for native workflow integration between document control, risk, CAPA and Technical File modules — being able to pull a traceability report in seconds is worth the subscription for teams approaching a notified‑body audit.

What single MDR requirement gives your team the most trouble in audits — PRRC, clinical evaluation/PMCF, Annex II traceability, or something else?